Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Spencer Meier

Physician Assistant, Medical Las Vegas, NV Physician Assistant

NPI 1306103148 CMS profile 11192228

6460 Medical Center St Ste 350, Las Vegas, NV 89148

Open in the dashboard

General payments

$24,154

932 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Spencer Meier of Las Vegas, NV is reported in the CMS Open Payments database as having received $24,154 across 932 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,251 224
2024 General $5,564 295
2023 General $5,547 189
2022 General $3,793 130
2021 General $1,999 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Spencer Meier
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Spencer Meier were reported at $7,251. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Spencer Meier Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,999 $156 $41–$563 $132
2022 $3,793 $185 $55–$649 $149
2023 $5,547 $199 $58–$717 $160
2024 $5,564 $206 $62–$740 $164
2025 $7,251 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,566 133 payments
  2. Pfizer Inc. $2,877 69 payments
  3. Janssen Biotech, Inc. $2,292 103 payments
  4. Arcutis Biotherapeutics, Inc. $2,104 83 payments
  5. UCB, Inc. $1,354 62 payments
  6. Lilly USA, LLC $1,114 22 payments
  7. Sun Pharmaceutical Industries Inc. $942 39 payments
  8. Incyte Corporation $909 7 payments
  9. Ortho Dermatologics, a division of Bausch Health US, LLC $871 10 payments
  10. E.R. Squibb & Sons, L.L.C. $803 109 payments
  11. Other $6,323 295 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,576 905 payments
  2. Consulting Fee $4,610 7 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,110 2 payments
  4. Education $858 18 payments
Products named General payments · program years 2021–2025
  1. CIBINQO $2,827 66 payments
  2. TREMFYA $2,259 101 payments
  3. RINVOQ $2,095 24 payments
  4. SKYRIZI $2,020 85 payments
  5. DUPIXENT $936 50 payments
  6. Bimzelx $921 31 payments
  7. Zoryve $842 63 payments
  8. VTAMA $791 49 payments
  9. TALTZ $721 18 payments
  10. SOTYKTU $680 103 payments
  11. Other $8,704 463 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

792

Median for Physician Assistant: 241

Drug cost

$221,828

Median for Physician Assistant: $4,110

Branded share of claims

13.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 11 $81,914
Dupixent Syringe Dupilumab Brand 18 $75,864
Dupixent Pen Dupilumab Brand 13 $47,393
Tacrolimus Generic 21 $2,278
Clobetasol Propionate Generic 47 $2,138
Triamcinolone Acetonide Generic 186 $1,641
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 54 $1,514
Tretinoin Generic 17 $1,332
Clindamycin Phosphate Generic 37 $1,100
Mometasone Furoate Generic 56 $1,023

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$136,561

Of which drugs: $43,838

Medicare patients

584

Average age 75

Services billed

3,492

261 women, 323 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 44%
Diabetes 30%
Ischemic heart disease 29%
Chronic kidney disease 20%
Cancer 18%
Atrial fibrillation 16%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 29 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$972 — —
CIBINQO
$792 — —
SKYRIZI
$455 — —
Zoryve
$442 — —
DUPIXENT
$438 31 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

932 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record